Repare Therapeutics Inc Stock

$1.37

0.72% yesterday

Nasdaq, May 20, 10:00 pm CET

ISIN

US7602731025

Symbol

RPTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Repare Therapeutics Inc Stock price

$1.37

-29.43 95.55% 5Y

Nasdaq, Closing price Tue, May 20 2025

-0.01 0.72%

ISIN

US7602731025

Symbol

RPTX

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$58.76m
Enterprise Value	$-64.10m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	0.55
EV/Sales (TTM) EV/Sales	-59.91
P/S ratio (TTM) P/S ratio	54.92
P/B ratio (TTM) P/B ratio	0.47
Revenue growth (TTM) Revenue growth	-98.90%
Revenue (TTM) Revenue	$1.07m
EBIT (operating result TTM) EBIT	$-130.11m
Free Cash Flow (TTM) Free Cash Flow	$-117.51m
Cash position	$124.23m
EPS (TTM) EPS	$-3.01
P/E forward	negative
P/S forward	8.81
EV/Sales forward	negative
Short interest	1.75%

As a Free StocksGuide user, you can view scores for all 6,789 stocks worldwide.

Get Started for Free Today

Repare Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

3 Analysts have issued a Repare Therapeutics Inc forecast:

2x Buy

67%

1x Hold

33%

More details on Analyst Estimates Including Price Targets

3 Analysts have issued a Repare Therapeutics Inc forecast:

Buy

67%

Hold

33%

Analyst Estimates with Stock Price Targets

Financial data from Repare Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Mar '25		+/- %
Revenue	1.07 1.07	99% 99% 100%
- Direct Costs	2.61 2.61	16% 16% 244%
Gross Profit	-1.53 -1.53	102% 102% -143%
- Selling and Administrative Expenses	26 26	13% 13% 2,397%
- Research and Development Expense	100 100	24% 24% 9,376%
EBITDA	-128 -128	92% 92% -11,916%
- Depreciation and Amortization	2.61 2.61	16% 16% 244%
EBIT (Operating Income) EBIT	-130 -130	87% 87% -12,160%
Net Profit	-128 -128	180% 180% -11,952%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Repare Therapeutics Inc Stock News

Neutral

Business Wire

●

7 days ago

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2025 Financial Results

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a clinical-stage precision oncology company, today reported financial results for the first quarter ended March 31, 2025. “During the first quarter of 2025 we continued our efforts to create long-term value for our shareholders via partnering and by advancing our novel pipeline pro...

Neutral

Business Wire

●

20 days ago

Repare Therapeutics Announces Out-Licensing of its Discovery Platforms to DCx Biotherapeutics

CAMBRIDGE, Mass. & MONTREAL--(BUSINESS WIRE)--Repare Therapeutics Inc. (“Repare”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced that it has out-licensed its discovery platforms, including certain platform and program intellectual property, to DCx Biotherapeutics Corporation (“DCx”), a newly-launched Canadian biotechnology company developing next generation...

Neutral

Business Wire

●

20 days ago

Newly Launched DCx Biotherapeutics In-Licenses Discovery Platforms and Retains Talent and Infrastructure From Repare Therapeutics to Accelerate Development of Multi-Modal Antibody Drug Conjugates

VANCOUVER--(BUSINESS WIRE)--DCx Biotherapeutics Corporation (“DCx”) today announced an agreement with Repare Therapeutics Inc. (“Repare”) (NASDAQ: RPTX) to (i) in-license Repare's discovery platform including certain program intellectual property, (ii) retain talent, (iii) acquire lease rights to laboratory facilities in Montreal and (iv) acquire laboratory equipment (the “Transaction”). Combin...

More Repare Therapeutics Inc News

Company Profile

Repare Therapeutics Inc., a precision oncology company, discovers and develops novel therapeutics by using synthetic lethality approach in Canada. It provides SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. The company's lead product candidate is RP-3500 a potent and selective oral small molecule inhibitor of ATR for the treatment of tumors with mutations in ataxia-telangiectasia mutated kinase. It also develops CCNE1-SL, a proprietary drug discovery program for tumors with amplification of CCNE1; and polymerase theta inhibitor. The company was founded in 2016 and is headquartered in St. Laurent, Canada.

Head office	Canada
CEO	Steve Forte
Employees	129
Founded	2016
Website	www.reparerx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now